Scienjoy Holding Corporation - Class A Ordinary Shares (SJ)
0.8702
-0.0098 (-1.11%)
NASDAQ · Last Trade: Apr 4th, 5:45 PM EDT

Via Benzinga · April 24, 2024

Via Benzinga · March 15, 2024

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
Via Benzinga · February 16, 2024

Via Benzinga · February 13, 2024

Scienjoy Holding just reported results for the third quarter of 2023.
Via InvestorPlace · December 15, 2023

Via Benzinga · January 28, 2025

Via Benzinga · September 26, 2024

Scienjoy Holding just reported results for the first quarter of 2024.
Via InvestorPlace · June 6, 2024

Via Benzinga · May 10, 2024

Scienjoy Holding just reported results for the fourth quarter of 2023.
Via InvestorPlace · April 26, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via Benzinga · February 29, 2024

Via Benzinga · February 9, 2024

Via Benzinga · February 7, 2024

Via Benzinga · February 6, 2024

Via Benzinga · February 5, 2024

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.
Via Benzinga · February 5, 2024

Via Benzinga · February 2, 2024

Via Benzinga · November 27, 2023

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.
Via Benzinga · February 2, 2024

Via Benzinga · October 16, 2023

Gainers Oblong, Inc. (NASDAQ: OBLG) shares rose 295.7% to $1.16 in pre-market trading.
Via Benzinga · October 13, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via Benzinga · November 7, 2023

Via Benzinga · October 9, 2023

Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.
Via Benzinga · September 28, 2023